| http://www.w3.org/ns/prov#value | - That arm recently inked a deal with US-based biopharma firm Adventrix Pharmaceuticals in which Fabre will contract manufacture (in clinical trials) the active ingredient in ANX-188, Adventrix???s lead candidate that indicates improves microvascular blood flow and has potential application in treating a wide range of diseases and conditions, such as complications arising from sickle cell disease.
|
